Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medical Interventions in Insulin Resistance
NCT02502344Phase 4Unknown
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Aug 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin in insulin resistance (IR) (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: prevalence of abnormal glucose intolerance at 2 years. Status: unknown.
02
Drugs
metformin
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT02502344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502344.